ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project.

Neurology
Jarith L EbenauWiesje M van der Flier

Abstract

To investigate the relationship between the ATN classification system (amyloid, tau, neurodegeneration) and risk of dementia and cognitive decline in individuals with subjective cognitive decline (SCD). We classified 693 participants with SCD (60 ± 9 years, 41% women, Mini-Mental State Examination score 28 ± 2) from the Amsterdam Dementia Cohort and Subjective Cognitive Impairment Cohort (SCIENCe) project according to the ATN model, as determined by amyloid PET or CSF β-amyloid (A), CSF p-tau (T), and MRI-based medial temporal lobe atrophy (N). All underwent extensive neuropsychological assessment. For 342 participants, follow-up was available (3 ± 2 years). As a control population, we included 124 participants without SCD. Fifty-six (n = 385) participants had normal Alzheimer disease (AD) biomarkers (A-T-N-), 27% (n = 186) had non-AD pathologic change (A-T-N+, A-T+N-, A-T+N+), 18% (n = 122) fell within the Alzheimer continuum (A+T-N-, A+T-N+, A+T+N-, A+T+N+). ATN profiles were unevenly distributed, with A-T+N+, A+T-N+, and A+T+N+ containing very few participants. Cox regression showed that compared to A-T-N-, participants in A+ profiles had a higher risk of dementia with a dose-response pattern for number of biomarkers affecte...Continue Reading

References

Aug 1, 1987·AJR. American Journal of Roentgenology·F FazekasR A Zimmerman
Jan 1, 1982·Journal of Psychiatric Research·J A YesavageV O Leirer
Feb 1, 2011·Annals of Neurology·Victor L VillemagneChristopher C Rowe
Feb 18, 2011·Neurology·M L Gorno-TempiniM Grossman
Jul 23, 2011·Stroke; a Journal of Cerebral Circulation·Philip B GorelickUNKNOWN American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Counci
Aug 2, 2011·European Radiology·Esther L G E KoedamMike P Wattjes
Aug 4, 2011·Brain : a Journal of Neurology·Katya RascovskyBruce L Miller
May 5, 2012·Brain : a Journal of Neurology·Rik OssenkoppeleBart N M van Berckel
Dec 13, 2012·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Argonde C van HartenWiesje M van der Flier
Sep 10, 2013·Lancet Neurology·Stephanie Jb VosAnne M Fagan
Sep 21, 2013·Neurology·Argonde C van HartenWiesje M van der Flier
Jan 7, 2014·Clinical Biochemistry·Charlotte E TeunissenBrit Mollenhauer
Mar 13, 2014·Journal of Alzheimer's Disease : JAD·Wiesje M van der FlierPhilip Scheltens
Apr 22, 2014·Neurology·Rik OssenkoppeleBart N M van Berckel
May 7, 2014·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Frank JessenUNKNOWN Subjective Cognitive Decline Initiative (SCD-I) Working Group
Aug 27, 2014·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Flora H DuitsWiesje M van der Flier
Nov 9, 2016·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·José L MolinuevoUNKNOWN Subjective Cognitive Decline Initiative (SCD-I) Working Group
Jan 6, 2017·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Sander C J VerfaillieWiesje M van der Flier
Jan 18, 2017·Alzheimer's Research & Therapy·Marissa D ZwanPhilip Scheltens
Feb 28, 2017·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Arno de WildeWiesje M van der Flier
Dec 7, 2017·Clinical Chemistry·Betty M TijmsCharlotte E Teunissen
Jan 22, 2018·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Beth E SnitzMary Ganguli
Mar 23, 2018·Journal of Alzheimer's Disease : JAD·Wiesje M van der Flier, Philip Scheltens
Mar 25, 2018·Neurology·Susan M LandauUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Apr 15, 2018·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Clifford R JackUNKNOWN Contributors
Aug 5, 2018·Alzheimer's Research & Therapy·Elles KonijnenbergPieter Jelle Visser
Aug 8, 2018·Alzheimer's Research & Therapy·Rosalinde E R SlotWiesje M Van der Flier
Sep 4, 2018·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Ignacio Illán-GalaJuan Fortea
Oct 16, 2018·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Marie BruunWiesje M van der Flier
Nov 9, 2018·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Eline A J WillemseCharlotte E Teunissen
Dec 18, 2018·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Rosalinde E R SlotWiesje M van der Flier
Jun 19, 2019·JAMA : the Journal of the American Medical Association·Clifford R JackRonald C Petersen
Oct 11, 2019·Neurology·Daniele AltomareWiesje M van der Flier

❮ Previous
Next ❯

Citations

Jan 10, 2021·Annals of Clinical and Translational Neurology·Wiesje PelkmansBetty M Tijms
Feb 3, 2021·Healthcare·Seunghyeon LeeHyo-Bum Kwak
Feb 10, 2021·Neurobiology of Aging·Jaime D MondragónUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Mar 6, 2021·Lancet·Philip ScheltensWiesje M van der Flier
Mar 27, 2021·Alzheimer's Research & Therapy·Anna RosenbergUNKNOWN LipiDiDiet clinical study group
May 8, 2021·Scientific Reports·Elisabeth H ThijssenCharlotte E Teunissen
Jul 27, 2021·Journal of Alzheimer's Disease : JAD·Daniel E GustavsonWilliam S Kremen
Jul 10, 2021·Nature Reviews. Neurology·Harald HampelAndrea Vergallo
Jul 22, 2021·Nature Reviews. Neurology·Meichen YuAndrew J Saykin
Aug 3, 2021·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Karolina G César-FreitasRicardo Nitrini
Oct 13, 2021·Alzheimer's Research & Therapy·Leonie N C VisserJosé Luis Molinuevo
Dec 9, 2021·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Olin JanssenPieter Jelle Visser

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISAs

Software Mentioned

R

Related Concepts

Related Feeds

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.